|
|
 |
|
Viewing report
|
|
|
|
U.S. Diabetes Pipeline Outlook
Frost & Sullivan, Nov 2006, Pages: 72
This research service covers the pharmaceutical industry development pipeline for diabetes mellitus in the United States, with 2005 as the base year. Included are both the products projected to enter the market by the end of the forecast coverage period in 2012, as well as products entering the market in 2005 that correspond to the in-depth discussion drug classes. The focus of this piece is on pipeline technology developments and has greater focus on: GLP-1 Agonists, DPP-IV Inhibitors; PPAR Modulators; and Pulmonary Insulin. Also discussed are pipeline developments in other areas of oral antidiabetic drugs, injectables, and insulins other than pulmonary. Product Analysis charts are included for those products in Phase III clinical trials.
The following technologies are covered in this research:
-GLP-1 agonists
-DPP-IV inhibitors
-Pulmonary insulin
-PPAR modulators
-Other pipeline efforts
Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:
-Pharmaceuticals
-Cardiology
-Biotechnology
-Diabetes
|
|
|
|
